SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-307303
Filing Date
2022-12-16
Accepted
2022-12-16 16:04:17
Documents
12
Period of Report
2022-12-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d433742d8k.htm   iXBRL 8-K 24227
  Complete submission text file 0001193125-22-307303.txt   145258

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20221213.xsd EX-101.SCH 2854
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20221213_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20221213_pre.xml EX-101.PRE 11264
6 EXTRACTED XBRL INSTANCE DOCUMENT d433742d8k_htm.xml XML 3369
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 221467937
SIC: 2836 Biological Products, (No Diagnostic Substances)